Variable | Univariate analysis | |||
---|---|---|---|---|
N | OR | [95% CI] | p-value | |
Age (years) | ||||
< 65 | 11/61 | 1.00 | ||
≥65 | 17/68 | 1.52 | [0.65–3.56] | 0.34 |
Sex | ||||
Male | 17/68 | 1.00 | ||
Female | 11/61 | 0.66 | [0.28–1.55] | 0.34 |
ECOG PS | ||||
0–1 | 13/77 | 1.00 | ||
2–4 | 15/52 | 2.00 | [0.86–4.65] | 0.11 |
Disease status | ||||
Advanced | 28/120 | NC | NC | |
Recurrent | 0/9 | |||
Primary site | ||||
Stomach | 26/123 | 1.00 | ||
GEJ (vs. stomach) | 2/6 | 1.87 | [0.32–10.76] | 0.49 |
No. of metastatic sites | ||||
1–2 | 19/100 | 1.00 | ||
≥3 | 9/29 | 1.92 | [0.76–4.87] | 0.17 |
Subtype of SPM | ||||
Massive ascites | 16/62 | 1.00 | ||
Inadequate oral intake | 7/35 | 0.72 | [0.26–1.96] | 0.52 |
Both | 5/32 | 0.53 | [0.18–1.62] | 0.27 |
Serum albumin level | ||||
> 3.1 g/ml | 10/68 | 1.00 | ||
< 3.1 g/ml | 18/61 | 2.43 | [1.02–5.78] | 0.05 |
Serum CRP level | ||||
< 2.2 mg/dl | 8/62 | 1.00 | ||
> 2.2 mg/dl | 20/67 | 2.87 | [1.16–7.13] | 0.02 |